MIST - Wutah pendapatan taun lumaku milestonepharma.com

The TTM revenue growth rate for Milestone Pharmaceuticals (MIST), which stands at 0.00, complements the profile of this cardiology biopharmaceutical company characterized by an academic culture and a strong R&D team. The development of tachycardia treatments here relies on automated synthesis and physician expertise, while the strategy is based on the support of a commercial partner to secure regulatory approvals.
milestonepharma.com (MIST) - rincian metrik lan laporan keuangan

Demand for Milestone Pharmaceuticals (MIST) cardiology drugs is independent of macro cycles, although the cost of funding development remains sensitive to the capital market. The relative change in rolling year revenue compared to the same period last year measures business growth rates, allowing investors to filter out short-term noise and assess the company's actual resilience to shocks by analyzing the trend on this chart.